Clin Kidney J . Long-term impact of COVID-19 among maintenance haemodialysis patients

[tetano]

Clin Kidney J


. 2021 Sep 27;15(2):262-268.
doi: 10.1093/ckj/sfab166. eCollection 2022 Feb.
Long-term impact of COVID-19 among maintenance haemodialysis patients


Sylvain Chawki ¹ , Albert Buchard ² , Hamza Sakhi ^{3 4} , Karim Dardim ⁵ , Karim El Sakhawi ³ , Mokhtar Chawki ⁶ , Henri Boulanger ⁷ , Tomek Kofman ⁸ , Djamal Dahmane ^{3 4} , Philippe Rieu ⁹ , David Attaf ¹⁰ , Salima Ahriz-Saksi ⁷ , Afshin Masoumi ⁸ , Ali Zineddine Diddaoui ⁶ , Luc Fromentin ⁶ , Patrick Michaut ¹¹ , Rachida Nebbad ¹² , Jean-François Desassis ¹³ , Laurence Nicolet ¹³ , Julie Sohier-Attias ¹⁴ , Frederic Besson ¹⁵ , Remy Boula ¹⁵ , Ali Hafi ¹⁵ , Abderrahmane Ghazali ¹⁶ , Larbi Lamriben ¹⁷ , Adem Arezki ¹⁷ , Emmanuel Dupuis ¹⁸ , Mohamad-Khair Rifard ¹⁹ , Dominique Joly ²⁰ , Philippe Attias ⁹ , Khalil El Karoui ^{3 4}



Affiliations

• PMID: 35140935
• PMCID: PMC8522382
• DOI: 10.1093/ckj/sfab166

Abstract

Background: Maintenance haemodialysis (MHD) patients have a high risk of initial mortality from coronavirus disease 2019 (COVID-19). However, long-term consequences of this disease in the MHD population are poorly described. We report the clinical presentation, outcome and long-term follow-up of MHD patients affected by COVID-19 in a multicentric cohort from the Paris, France area.
Methods: We conducted a retrospective analysis of clinical presentation and long-term follow-up of MHD patients affected by COVID-19 in 19 MHD centres in the Paris, France area.
Results: In this cohort of 248 patients with an initial mortality rate of 18%, age, comorbidities, dyspnoea and previous immunosuppressive treatment were associated with death at <30 days. Among the 203 surviving patients following the acute phase, long-term follow-up (median 180 days) was available for 189 (93%) patients. Major adverse events occurred in 30 (16%) patients during follow-up, including 12 deaths (6%) after a median of 78 days from onset of symptoms. Overall, cardiovascular events, infections and gastrointestinal bleeding were the main major adverse events. Post-COVID-19 cachexia was observed in 25/189 (13%) patients. Lower initial albuminaemia was significantly associated with this cachexia. No reinfection with severe acute respiratory syndrome coronavirus 2 was observed.
Conclusions: This work demonstrates the long-term consequences of COVID-19 in MHD patients, highlighting both initial and long-term severity of the disease, including severe cachexia.

Keywords: COVID-19; SARS-CoV-2; cachexia; haemodialysis; long-term follow-up; mortality; nutritional status.